JP2024539265A5 - - Google Patents
Info
- Publication number
- JP2024539265A5 JP2024539265A5 JP2024524494A JP2024524494A JP2024539265A5 JP 2024539265 A5 JP2024539265 A5 JP 2024539265A5 JP 2024524494 A JP2024524494 A JP 2024524494A JP 2024524494 A JP2024524494 A JP 2024524494A JP 2024539265 A5 JP2024539265 A5 JP 2024539265A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid formulation
- stable liquid
- formulation according
- approximately
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115121.2 | 2021-10-21 | ||
| GBGB2115121.2A GB202115121D0 (en) | 2021-10-21 | 2021-10-21 | Formulations |
| PCT/EP2022/079182 WO2023067049A1 (en) | 2021-10-21 | 2022-10-20 | Formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539265A JP2024539265A (ja) | 2024-10-28 |
| JP2024539265A5 true JP2024539265A5 (https=) | 2025-10-21 |
Family
ID=78806158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524494A Pending JP2024539265A (ja) | 2021-10-21 | 2022-10-20 | 製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240415769A1 (https=) |
| EP (1) | EP4419078A1 (https=) |
| JP (1) | JP2024539265A (https=) |
| KR (1) | KR20240099311A (https=) |
| CN (1) | CN118119377A (https=) |
| AR (1) | AR127421A1 (https=) |
| AU (1) | AU2022372646A1 (https=) |
| CA (1) | CA3235381A1 (https=) |
| CL (1) | CL2024001229A1 (https=) |
| CO (1) | CO2024006193A2 (https=) |
| GB (1) | GB202115121D0 (https=) |
| GE (2) | GEAP202416520A (https=) |
| IL (1) | IL312207A (https=) |
| MX (1) | MX2024004872A (https=) |
| PE (1) | PE20241193A1 (https=) |
| TW (1) | TW202323288A (https=) |
| WO (1) | WO2023067049A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| GB201209096D0 (en) | 2012-05-24 | 2012-07-04 | Medical Res Council Technology | Compounds |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| CN109563161A (zh) * | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
-
2021
- 2021-10-21 GB GBGB2115121.2A patent/GB202115121D0/en not_active Ceased
-
2022
- 2022-10-20 JP JP2024524494A patent/JP2024539265A/ja active Pending
- 2022-10-20 US US18/703,661 patent/US20240415769A1/en active Pending
- 2022-10-20 MX MX2024004872A patent/MX2024004872A/es unknown
- 2022-10-20 CN CN202280070135.8A patent/CN118119377A/zh active Pending
- 2022-10-20 GE GEAP202416520A patent/GEAP202416520A/en unknown
- 2022-10-20 KR KR1020247016530A patent/KR20240099311A/ko active Pending
- 2022-10-20 AR ARP220102861A patent/AR127421A1/es unknown
- 2022-10-20 IL IL312207A patent/IL312207A/en unknown
- 2022-10-20 TW TW111139753A patent/TW202323288A/zh unknown
- 2022-10-20 GE GEAP202216520A patent/GEP20257800B/en unknown
- 2022-10-20 EP EP22817522.0A patent/EP4419078A1/en active Pending
- 2022-10-20 PE PE2024000910A patent/PE20241193A1/es unknown
- 2022-10-20 CA CA3235381A patent/CA3235381A1/en active Pending
- 2022-10-20 WO PCT/EP2022/079182 patent/WO2023067049A1/en not_active Ceased
- 2022-10-20 AU AU2022372646A patent/AU2022372646A1/en active Pending
-
2024
- 2024-04-19 CL CL2024001229A patent/CL2024001229A1/es unknown
- 2024-05-16 CO CONC2024/0006193A patent/CO2024006193A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7473603B2 (ja) | 液体医薬組成物 | |
| JP2024109816A5 (https=) | ||
| JP2024075713A5 (https=) | ||
| JP2021073187A (ja) | 即効型インスリン組成物 | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| JP2022532927A5 (https=) | ||
| RU2008112146A (ru) | Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью | |
| AR040603A1 (es) | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| JP2007515469A5 (https=) | ||
| RU2007119724A (ru) | Композиции, содержащие эктинэсайдин и дисахарид | |
| JP2023518066A5 (https=) | ||
| WO2022135395A1 (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| JOP20220183A1 (ar) | صياغات أجسام مضادة ضد tslp بشرية وطرائق علاج مرض التهابي | |
| JP2024544415A5 (https=) | ||
| IL315632A (en) | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment | |
| JP2022514152A5 (https=) | ||
| JP2024512255A5 (https=) | ||
| JP2024539265A5 (https=) | ||
| JP2017519762A5 (https=) | ||
| CN112533639A (zh) | 掩蔽的抗体的药物配制品 | |
| JP2024539502A5 (https=) | ||
| JP2022523962A5 (https=) | ||
| RU2024113527A (ru) | Композиции | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease |